Bank of New York Mellon’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-133,225
| Closed | -$212K | – | 4324 |
|
|
2024
Q1 | $212K | Sell |
133,225
-5,865
| -4% | -$9.33K | ﹤0.01% | 3905 |
|
|
2023
Q4 | $119K | Sell |
139,090
-55
| -0% | -$47 | ﹤0.01% | 4051 |
|
|
2023
Q3 | $149K | Sell |
139,145
-391
| -0.3% | -$418 | ﹤0.01% | 4023 |
|
|
2023
Q2 | $361K | Buy |
139,536
+6,842
| +5% | +$17.7K | ﹤0.01% | 3747 |
|
|
2023
Q1 | $541K | Sell |
132,694
-721
| -0.5% | -$2.94K | ﹤0.01% | 3451 |
|
|
2022
Q4 | $670K | Sell |
133,415
-17,214
| -11% | -$86.4K | ﹤0.01% | 3398 |
|
|
2022
Q3 | $1.97M | Buy |
150,629
+19,840
| +15% | +$259K | ﹤0.01% | 2867 |
|
|
2022
Q2 | $1.68M | Sell |
130,789
-1,725
| -1% | -$22.1K | ﹤0.01% | 2935 |
|
|
2022
Q1 | $2.02M | Buy |
132,514
+3,893
| +3% | +$59.4K | ﹤0.01% | 2938 |
|
|
2021
Q4 | $2.28M | Buy |
128,621
+11,387
| +10% | +$202K | ﹤0.01% | 2913 |
|
|
2021
Q3 | $2.47M | Buy |
117,234
+15,843
| +16% | +$333K | ﹤0.01% | 2860 |
|
|
2021
Q2 | $2M | Buy |
101,391
+21,635
| +27% | +$427K | ﹤0.01% | 2981 |
|
|
2021
Q1 | $2.32M | Sell |
79,756
-3,399
| -4% | -$98.8K | ﹤0.01% | 2839 |
|
|
2020
Q4 | $2.52M | Sell |
83,155
-1,891
| -2% | -$57.3K | ﹤0.01% | 2706 |
|
|
2020
Q3 | $1.35M | Buy |
85,046
+3,857
| +5% | +$61.4K | ﹤0.01% | 2928 |
|
|
2020
Q2 | $1.6M | Sell |
81,189
-1,106
| -1% | -$21.8K | ﹤0.01% | 2805 |
|
|
2020
Q1 | $1.02M | Buy |
82,295
+23,567
| +40% | +$291K | ﹤0.01% | 2968 |
|
|
2019
Q4 | $1.09M | Buy |
58,728
+33,791
| +136% | +$624K | ﹤0.01% | 3205 |
|
|
2019
Q3 | $345K | Buy |
24,937
+12,928
| +108% | +$179K | ﹤0.01% | 3720 |
|
|
2019
Q2 | $176K | Buy |
+12,009
| New | +$176K | ﹤0.01% | 3936 |
|